


CLAIMS


1. Use of a therapeutically effective amount of Compound 1:




or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof in the manufacture of a medicament for the treatment of pain caused by inflammation in a subject in need thereof, wherein the medicament is to be administered to the subject.

2. The use of claim 1, wherein the pain is caused by initiation of the inflammatory response.
3. The use of any of the foregoing claims, wherein the pain is associated with hyperalgesia.
4. The use of any of the foregoing claims, wherein the pain is chronic pain or subacute pain.
5. The use of any of the foregoing claims, wherein the chronic pain is arthritis pain, low back pain, neuropathic pain, visceral pain, pain due to cancer, pain due to injury, pain due to joint inflammation, pain due to back disorders, or neck pain.
6. The use of claim 5, wherein the pain due to cancer is caused by cancer involving intraperitoneal abdominal and pelvic organs or bone cancer or bone metastases.
7. The use of claim 5, wherein the pain due to injury is caused by bone, ligament, or tendon injury.
8. The use of any of the foregoing claims, wherein Compound 1 reduces pain to a similar degree as a central-nervous system-acting opioid.
9. The use of claim 8, wherein the central-nervous system-acting opioid activates a *mu* receptor.
10. The use of claim 8, wherein the central-nervous system-acting opioid is morphine.
11. The use of any of the foregoing claims, wherein administration of the medicament does not result in any central-nervous system side effects.


12. The use of claim 11, wherein the central nervous system side-effects are addiction, constipation, sedation, impaired mentation, somnolence, respiratory depression, nausea, dysphoria, or seizures.
13. The use of claim 12, wherein administration of the medicament does not result in constipation.
14. The use of claim 12, wherein administration of the medicament does not result in addiction.
15. The use of any of the foregoing claims, wherein Compound 1 results in synergistic activation of *kappa* and *delta* opioid receptors.
16. The use of claim 15, wherein the synergy results from allosteric modulation of *kappa* receptors by *delta* receptor activity.
17. The use of any of the foregoing claims, wherein administration of Compound 1 is similar or superior to a *kappa* receptor agonist for treatment of acute pain.
18. The use of any of the foregoing claims, wherein administration of Compound 1 is similar or superior to a *kappa* receptor agonist for treatment of hyperalgesia.
19. The use of any of the foregoing claims, wherein administration of Compound 1 results in reduced urinary output compared to a *kappa* receptor agonist.
20. Use of the Compound 1:






or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof in the manufacture of a medicament for the prevention of pain caused by inflammation or the initiation of the inflammatory response.

22. A pharmaceutical composition comprising Compound 1:



and a pharmaceutically acceptable carrier.

23. Compound 1:



for use in therapy.